NICE recommends Remicade for Ulcerative Colitis-Merck Inc.

In its Final Appraisal Document, NICE has recommended Remicade (infliximab), from Merck, within their marketing authorisations, as options for treating moderately to severely active Ulcerative Colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine.

Additionally, the NICE FAD recommends Remicade, within its marketing authorisation, as an option for treating severely active UC in children and young people aged 6-17 years whose disease has responded inadequately to conventional therapy, including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies. This is the first time that children with moderately to severely active UC have been granted access to these therapies in the UK.